Pediatric Praziquantel Consortium

Publication: Schistosomiasis Control: Leave No Age Group Behind

19 June 2020

The current treatment and monitoring strategies for schistosomiasis control programs mainly focus on school-aged...

Publication: Sensitive diagnostic tools and targeted drug administration strategies needed to eliminate schistosomiasis

18 May 2020

While current treatment strategies have been instrumental in managing the disease burden of schistosomiasis, there...

A new formulation to fight Schistosomiasis

A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more